Premium
Hydroxyurea to Inhibit Human Immunodeficiency Virus‐1 Replication
Author(s) -
Romanelli Frank,
Pomeroy Claire,
Smith Kelly M.
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.3.196.30913
Subject(s) - ribonucleotide reductase , human immunodeficiency virus (hiv) , adverse effect , protease inhibitor (pharmacology) , medicine , virology , drug , reverse transcriptase , nucleoside analogue , immunology , biology , nucleoside , pharmacology , antiretroviral therapy , viral load , rna , genetics , protein subunit , gene
Treatment of human immunodeficiency virus (HIV) infection continues to be a challenge. Drug regimens that include two nucleoside reverse transcriptase inhibitors and a protease inhibitor are now the standard of care. These regimens require strict patient adherence and have numerous adverse effects at a high cost, so clinicians must continue to explore other therapeutic options. Hydroxyurea is a ribonucleotide reductase inhibitor that may have efficacy against HIV. We conducted a critical review of the literature to examine the utility of hydroxyurea‐based drug combinations.